$CLNN
Clene Inc. Stock $clnn

$clnn Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000095017022022333 Filed on November 07, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$234.0K	$174.0K	$110.0K
YoY Change	17.59%	58.18%
Cost Of Revenue	$7.000K	$19.00K	$14.00K
YoY Change	-101.34%	35.71%
Gross Profit	$227.0K	$155.0K	$96.00K
YoY Change	-68.56%	61.46%
Gross Profit Margin	97.01%	89.08%	87.27%
Selling, General & Admin	$4.063M	$3.490M	$4.371M
YoY Change	-22.71%	-20.16%	792.04%
% of Gross Profit	1789.87%	2251.61%	4553.13%
Research & Development	$7.533M	$6.403M	$5.946M
YoY Change	-19.2%	7.69%	56.89%
% of Gross Profit	3318.5%	4130.97%	6193.75%
Depreciation & Amortization	$304.0K	$233.0K	$235.0K
YoY Change	37.56%	-0.85%	-2.08%
% of Gross Profit	133.92%	150.32%	244.79%
Operating Expenses	$11.90M	$9.979M	$10.55M
YoY Change	-19.49%	-5.38%	2052.24%
Operating Profit	-$11.67M	-$9.805M	-$10.45M
YoY Change	-16.97%	-6.17%	2032.65%
Interest Expense	$8.268M	-$2.448M	$35.12M
YoY Change	-46.69%	-106.97%
% of Operating Profit
Other Income/Expense, Net	$2.351M	-$1.171M	$4.203M
YoY Change	-14.73%	-127.86%	-213.29%
Pretax Income	-$1.054M	-$10.98M	$28.88M
YoY Change	-125.05%	-138.01%	-6115.63%
Income Tax	$0.00	$0.00	-$69.00K
% Of Pretax Income			-0.24%
Net Earnings	-$1.054M	-$10.98M	$28.94M
YoY Change	-123.83%	-137.92%	-6130.0%
Net Earnings / Revenue	-450.43%	-6308.05%	26312.73%
Basic Earnings Per Share		-$0.17	$0.47
Diluted Earnings Per Share	-$0.01	-$0.17	$0.42
COMMON SHARES
Basic Shares Outstanding	73.82M	63.50M	62.07M shares
Diluted Shares Outstanding		63.51M	70.04M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.32M	$16.23M	$60.55M
YoY Change	-53.64%	-73.19%	13661.82%
Cash & Equivalents	$18.33M	$7.267M	$60.61M
Short-Term Investments	$4.983M	$8.966M
Other Short-Term Assets	$581.0K	$3.491M	$3.520M
YoY Change	-78.0%	-0.82%	3811.11%
Inventory	$43.00K	$38.00K	$41.00K
Prepaid Expenses
Receivables	$189.0K	$126.0K	$68.00K
Other Receivables	$2.777M	$1.598M	$1.212M
Total Short-Term Assets	$29.20M	$21.49M	$65.39M
YoY Change	-46.51%	-67.14%	12238.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.24M	$9.753M	$7.586M
YoY Change	194.66%	28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$58.00K	$58.00K	$58.00K
YoY Change	0.0%	0.0%	-99.77%
Total Long-Term Assets	$15.30M	$14.52M	$7.644M
YoY Change	80.4%	89.93%	-70.13%
TOTAL ASSETS
Total Short-Term Assets	$29.20M	$21.49M	$65.39M
Total Long-Term Assets	$15.30M	$14.52M	$7.644M
Total Assets	$44.49M	$36.00M	$73.04M
YoY Change	-29.45%	-50.7%	179.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.014M	$3.454M	$1.023M
YoY Change	56.73%	237.63%
Accrued Expenses	$3.863M	$2.136M	$3.379M
YoY Change	7.01%	-36.79%	1777.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$6.492M	$97.00K	$153.0K
YoY Change	4346.58%	-36.6%
Total Short-Term Liabilities	$13.86M	$6.154M	$4.831M
YoY Change	129.95%	27.39%	42.09%
LONG-TERM LIABILITIES
Long-Term Debt	$19.29M	$20.53M	$19.30M
YoY Change	0.56%	6.41%
Other Long-Term Liabilities	$8.112M	$18.64M	$43.16M
YoY Change	-67.89%	-56.82%	3004.68%
Total Long-Term Liabilities	$27.40M	$39.17M	$62.45M
YoY Change	-38.35%	-37.28%	4392.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.86M	$6.154M	$4.831M
Total Long-Term Liabilities	$27.40M	$39.17M	$62.45M
Total Liabilities	$41.26M	$45.32M	$67.35M
YoY Change	-18.25%	-32.71%	1306.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$193.2M	-$192.2M
YoY Change	18.31%
Common Stock	$7.000K	$6.000K
YoY Change	16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.237M	-$9.319M	$5.686M
YoY Change
Total Liabilities & Shareholders Equity	$44.49M	$36.00M	$73.04M
YoY Change	-29.45%	-50.7%	179.62%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$1.054M	-$10.98M	$28.94M
YoY Change	-123.83%	-137.92%	-6130.0%
Depreciation, Depletion And Amortization	$304.0K	$233.0K	$235.0K
YoY Change	37.56%	-0.85%	-2.08%
Cash From Operating Activities	-$7.716M	-$8.481M	-$7.305M
YoY Change	-19.68%	16.1%	1228.18%
INVESTING ACTIVITIES
Capital Expenditures	$1.701M	-$1.654M	-$241.0K
YoY Change	-353.5%	586.31%	-401.25%
Acquisitions
YoY Change
Other Investing Activities	$3.983M	$10.07M
YoY Change
Cash From Investing Activities	$2.282M	$8.411M	-$241.0K
YoY Change	-440.09%	-3590.04%	201.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	16.37M	92.00K	5.232M
YoY Change	-91066.67%	-98.24%	616.71%
NET CHANGE
Cash From Operating Activities	-7.716M	-8.481M	-7.305M
Cash From Investing Activities	2.282M	8.411M	-241.0K
Cash From Financing Activities	16.37M	92.00K	5.232M
Net Change In Cash	10.94M	22.00K	-2.314M
YoY Change	-206.27%	-100.95%	-1385.56%
FREE CASH FLOW
Cash From Operating Activities	-$7.716M	-$8.481M	-$7.305M
Capital Expenditures	$1.701M	-$1.654M	-$241.0K
Free Cash Flow	-$9.417M	-$6.827M	-$7.064M
YoY Change	5.39%	-3.36%	1021.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	547000
	us-gaap	Revenues Revenues	524000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	511000
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3478000
	dei	Entity Registrant Name EntityRegistrantName	CLENE INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2828339
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6550 South Millrock Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite G50
	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84121
	dei	City Area Code CityAreaCode	801
	dei	Local Phone Number LocalPhoneNumber	676-9695
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	CLNN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001822791
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	01-39834
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73820010
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	14484000
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	192000
CY2022Q3	clnn	Convertible Note Payable ConvertibleNotePayable	4763000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	661000
CY2021Q4	clnn	Convertible Note Payable ConvertibleNotePayable	4598000
CY2022Q3	clnn	Common Stock Warrant Liability CommonStockWarrantLiability	18000
	clnn	Common Stock Warrant Liability Recorded At Issuance Of Notes Payable CommonStockWarrantLiabilityRecordedAtIssuanceOfNotesPayable	1457000
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8966000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0
	clnn	Cash Paid For Interest Expense CashPaidForInterestExpense	1646000
CY2021Q4	clnn	Common Stock Warrant Liability CommonStockWarrantLiability	474000
CY2022Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	11438000
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	18100000
CY2022Q3	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	1468000
CY2021Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	2317000
CY2022Q3	us-gaap	Liabilities Liabilities	45323000
CY2021Q4	us-gaap	Liabilities Liabilities	50466000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	126000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	49000
CY2022Q3	us-gaap	Inventory Net InventoryNet	38000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-360000
CY2021Q4	us-gaap	Inventory Net InventoryNet	41000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63541984
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63541984
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5089000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4205000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62312097
CY2022Q3	us-gaap	Assets Current AssetsCurrent	21486000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62312097
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	6000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	146000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	54583000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6154000
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6026000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4707000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3250000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9753000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5711000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4370000
CY2022Q3	us-gaap	Assets Assets	36004000
CY2021Q4	us-gaap	Assets Assets	63063000
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	45000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3454000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1923000
	us-gaap	Revenues Revenues	239000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	97000
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	15726000
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7267000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50288000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2136000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3610000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	467000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	347000
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	97000
	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	151000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	182760000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	175659000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-192165000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163301000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	80000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	233000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-9319000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12597000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36004000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63063000
CY2022Q3	us-gaap	Revenues Revenues	174000
CY2021Q3	us-gaap	Revenues Revenues	110000
CY2022Q3	clnn	Costs Of Revenue CostsOfRevenue	19000
CY2021Q3	clnn	Costs Of Revenue CostsOfRevenue	14000
	clnn	Costs Of Revenue CostsOfRevenue	19000
	clnn	Costs Of Revenue CostsOfRevenue	812000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6403000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6146000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24149000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18893000
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3557000
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4400000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12807000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16739000
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	9979000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	10560000
	us-gaap	Operating Expenses OperatingExpenses	36975000
	us-gaap	Operating Expenses OperatingExpenses	36444000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9805000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10450000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36736000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-35920000
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-857000
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	80000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2390000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-497000
CY2022Q3	clnn	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	0
CY2021Q3	clnn	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	0
	clnn	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	0
	clnn	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	647000
CY2022Q3	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0
CY2021Q3	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	420000
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0
CY2022Q3	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	149000
CY2021Q3	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	414000
CY2022Q3	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	-1591000
CY2021Q3	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	35042000
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	6662000
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	18072000
CY2022Q3	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	-205000
CY2021Q3	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	3439000
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	849000
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	1710000
CY2022Q3	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-1346000
CY2021Q3	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-364000
	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-2001000
	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-1078000
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	179000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1171000
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	39325000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7872000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21544000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10976000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	28875000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28864000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14376000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-69000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-213000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-10976000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	28944000
	us-gaap	Net Income Loss NetIncomeLoss	-28864000
	us-gaap	Net Income Loss NetIncomeLoss	-14163000
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	33000
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	0
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-54000
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	0
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-39000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-87000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-99000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-124000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	6000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	87000
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	153000
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	124000
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10982000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	28857000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29017000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14287000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.42
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63508928
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62071754
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63234757
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61307699
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63508928
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70038634
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63234757
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61307699
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12597000
CY2022Q1	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	305000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	267000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2202000
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-50000
CY2022Q1	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	50000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-13354000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2017000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2184000
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-37000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	100000
CY2022Q2	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	-110000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-4534000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-563000
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	128000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2098000
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	33000
CY2022Q3	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	-39000
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-10976000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-9319000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	341000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3265000
CY2021Q1	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	24000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-39756000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-36076000
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9250000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	58000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4255000
CY2021Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0
CY2021Q2	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	-61000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-3351000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-25925000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	319000
CY2021Q3	clnn	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	10000
CY2021Q3	clnn	Stock Issued During Period Exercise Of Underwriters Option StockIssuedDuringPeriodExerciseOfUnderwritersOption	0
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2425000
	clnn	Cash Paid For Interest Expense CashPaidForInterestExpense	631000
CY2021Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0
CY2021Q3	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	-87000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	28944000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	5686000
	us-gaap	Net Income Loss NetIncomeLoss	-28864000
	us-gaap	Net Income Loss NetIncomeLoss	-14163000
	us-gaap	Depreciation Depreciation	715000
	us-gaap	Depreciation Depreciation	734000
	us-gaap	Other Noncash Expense OtherNoncashExpense	285000
	us-gaap	Other Noncash Expense OtherNoncashExpense	81000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-151000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-547000
	clnn	Change In Fair Value Of Contingent Earnout Liability ChangeInFairValueOfContingentEarnoutLiability	-6662000
	clnn	Change In Fair Value Of Contingent Earnout Liability ChangeInFairValueOfContingentEarnoutLiability	-18072000
	clnn	Changes In Fair Value Of Initial Shareholders Contingent Earnout Liability ChangesInFairValueOfInitialShareholdersContingentEarnoutLiability	-849000
	clnn	Changes In Fair Value Of Initial Shareholders Contingent Earnout Liability ChangesInFairValueOfInitialShareholdersContingentEarnoutLiability	-1710000
	us-gaap	Share Based Compensation ShareBasedCompensation	6484000
	us-gaap	Share Based Compensation ShareBasedCompensation	9945000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	647000
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	420000
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-2000
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	661000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
	clnn	Non Cash Interest Income Expense NonCashInterestIncomeExpense	-83000
	clnn	Non Cash Interest Income Expense NonCashInterestIncomeExpense	134000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	77000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	48000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-150000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	884000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1230000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	213000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	446000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1474000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-142000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31295000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25018000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	24582000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	8000000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	7614000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12446000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-661000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	284000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	427000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	10000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	132000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	clnn	Payments Of At The Market Offering Commissions PaymentsOfAtTheMarketOfferingCommissions	4000
	clnn	Payments Of At The Market Offering Commissions PaymentsOfAtTheMarketOfferingCommissions	0
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	101000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	117000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	694000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	20000000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	30000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	534000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5000
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9250000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1901000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	875000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27130000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-155000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-116000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-43021000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1335000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50346000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59275000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7325000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60610000
CY2022Q3	us-gaap	Cash Cash	7267000
CY2021Q3	us-gaap	Cash Cash	60552000
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	58000
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	58000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7325000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60610000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2343000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2492000
	clnn	Lease Incentive Realized LeaseIncentiveRealized	500000
	clnn	Lease Incentive Realized LeaseIncentiveRealized	0
	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	602000
	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	0
	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	305000
	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	0
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1318000
	clnn	Common Stock Warrant Liability Recorded At Issuance Of Notes Payable CommonStockWarrantLiabilityRecordedAtIssuanceOfNotesPayable	0
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9800000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10500000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36700000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-35900000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-192200000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163300000
CY2022Q3	clnn	Cash Cash Equivalents Restricted Cash And Marketable Securities CashCashEquivalentsRestrictedCashAndMarketableSecurities	16200000
CY2021Q4	clnn	Cash Cash Equivalents Restricted Cash And Marketable Securities CashCashEquivalentsRestrictedCashAndMarketableSecurities	50300000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31300000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25000000.0
CY2021Q2	clnn	Minimum Cash Balance For Loan Covenant MinimumCashBalanceForLoanCovenant	5000000.0
CY2022Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	10800000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of condensed consolidated financial statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities, and the reported amounts of expenses. We base our estimates on historical experience and various other assumptions that we believe to be reasonable. Actual results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience, and any changes in estimates will be recorded in future periods as they develop.</span></p>
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	24000
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments which potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is mainly held in financial institutions. Amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p>
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	26000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15000
CY2020Q4	clnn	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	9400000
CY2020Q4	clnn	Net Proceeds From Reverse Recapitalization NetProceedsFromReverseRecapitalization	3500000
CY2020Q4	clnn	Shares Issued For Payment Of Offering Costs SharesIssuedForPaymentOfOfferingCosts	644164
	clnn	Clene Nanomedicine Contingent Earn Out Milestone1 Shares CleneNanomedicineContingentEarnOutMilestone1Shares	3333333
	clnn	Clene Nanomedicine Contingent Earnout Milestone1 Price CleneNanomedicineContingentEarnoutMilestone1Price	15.00
	clnn	Clene Nanomedicine Contingent Earnout Milestone2 Shares CleneNanomedicineContingentEarnoutMilestone2Shares	2500000
CY2022Q3	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	0
CY2021Q3	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	0
	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	0
	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	200000
	clnn	Clene Nanomedicine Contingent Earnout Milestone2 Price CleneNanomedicineContingentEarnoutMilestone2Price	20.00
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2021Q3	clnn	Operating Leases Rightof Use Assets OperatingLeasesRightofUseAssets	2400000
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2400000
	clnn	Clene Nanomedicine Contingent Earnout Milestone3 Shares CleneNanomedicineContingentEarnoutMilestone3Shares	2500000
	clnn	Total Clene Nanomedicine Contingent Earnout Shares TotalCleneNanomedicineContingentEarnoutShares	8346185
	clnn	Initial Shareholders Contingent Earnout Milestone One Shares InitialShareholdersContingentEarnoutMilestoneOneShares	375000
	clnn	Initial Shareholders Contingent Earnout Milestone2 Shares InitialShareholdersContingentEarnoutMilestone2Shares	375000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Milestone Three Shares Cancelled CleneNanomedicineContingentEarnoutMilestoneThreeSharesCancelled	2503851
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	9020000
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	54000
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	8966000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
CY2022Q3	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5500000
CY2021Q3	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	8000000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0
CY2022Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	4597000
CY2021Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	7614000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
CY2022Q3	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	10097000
CY2021Q3	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	15614000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0
	clnn	Debt Securities Available For Sale Maturity Period DebtSecuritiesAvailableForSaleMaturityPeriod	P1Y
CY2021Q3	us-gaap	Incentive To Lessee IncentiveToLessee	1000000.0
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	12000
CY2022Q3	clnn	Australia Research And Development Credit Receivable AustraliaResearchAndDevelopmentCreditReceivable	1598000
CY2021Q4	clnn	Australia Research And Development Credit Receivable AustraliaResearchAndDevelopmentCreditReceivable	1564000
CY2022Q3	clnn	Metals To Be Used In Research And Development MetalsToBeUsedInResearchAndDevelopment	2493000
CY2021Q4	clnn	Metals To Be Used In Research And Development MetalsToBeUsedInResearchAndDevelopment	2237000
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	998000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	404000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5089000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4205000
CY2022Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3410000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3327000
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	177000
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	147000
CY2022Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	459000
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	0
CY2022Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3956000
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3943000
CY2022Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	6684000
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2052000
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14686000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9469000
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4933000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4297000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9753000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2022Q3	us-gaap	Depreciation Depreciation	233000
CY2021Q3	us-gaap	Depreciation Depreciation	235000
	us-gaap	Depreciation Depreciation	715000
	us-gaap	Depreciation Depreciation	734000
CY2022Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	764000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2049000
CY2022Q3	clnn	Accrued Cro And Clinical Fees AccruedCroAndClinicalFees	744000
CY2021Q4	clnn	Accrued Cro And Clinical Fees AccruedCroAndClinicalFees	718000
CY2022Q3	clnn	Deferred Grant Funds DeferredGrantFunds	520000
CY2021Q4	clnn	Deferred Grant Funds DeferredGrantFunds	520000
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	108000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	323000
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2136000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3610000
CY2022Q3	clnn	Lease Incentive Recorded Construction In Progress LeaseIncentiveRecordedConstructionInProgress	1000000.0
CY2021Q4	clnn	Lease Incentive Recorded Construction In Progress LeaseIncentiveRecordedConstructionInProgress	500000
	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	The lease has an initial ten-year term and provides us the right and option to extend or renew for two periods of five years each. In accordance with ASC 842, Leases, the payments to be made in option periods have not been recognized as part of the right-of-use asset or lease liability because we do not assess the exercise of the option to be reasonably certain.
CY2022Q1	clnn	Operating Leases Rightof Use Assets OperatingLeasesRightofUseAssets	2300000
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2300000
CY2022Q1	clnn	Terminated Right Of Use Asset TerminatedRightOfUseAsset	600000
CY2022Q1	clnn	Terminated Operating Lease Liability TerminatedOperatingLeaseLiability	1000000.0
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	400000
CY2022Q3	clnn	Operating Lease Obligations Weighted Average Interest Rate OperatingLeaseObligationsWeightedAverageInterestRate	0.096
CY2021Q4	clnn	Operating Lease Obligations Weighted Average Interest Rate OperatingLeaseObligationsWeightedAverageInterestRate	0.096
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2022Q3	clnn	Finance Lease Laboratory Equipment Gross FinanceLeaseLaboratoryEquipmentGross	408000
CY2021Q4	clnn	Finance Lease Laboratory Equipment Gross FinanceLeaseLaboratoryEquipmentGross	408000
CY2022Q3	clnn	Finance Lease Work In Process Gross FinanceLeaseWorkInProcessGross	228000
CY2021Q4	clnn	Finance Lease Work In Process Gross FinanceLeaseWorkInProcessGross	228000
CY2022Q3	clnn	Finance Lease Liability Gross FinanceLeaseLiabilityGross	636000
CY2021Q4	clnn	Finance Lease Liability Gross FinanceLeaseLiabilityGross	636000
CY2022Q3	clnn	Accumulated Depreciation Depletion And Amortization Leases AccumulatedDepreciationDepletionAndAmortizationLeases	-305000
CY2021Q4	clnn	Accumulated Depreciation Depletion And Amortization Leases AccumulatedDepreciationDepletionAndAmortizationLeases	-244000
CY2022Q3	clnn	Finance Lease Liability Net FinanceLeaseLiabilityNet	331000
CY2021Q4	clnn	Finance Lease Liability Net FinanceLeaseLiabilityNet	392000
CY2022Q3	clnn	Finance Lease Obligations Weightedaverage Interest Rate FinanceLeaseObligationsWeightedaverageInterestRate	0.096
CY2021Q4	clnn	Finance Lease Obligations Weightedaverage Interest Rate FinanceLeaseObligationsWeightedaverageInterestRate	0.088
CY2022Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M18D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	20000
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	37000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	61000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	110000
CY2022Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6000
CY2021Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6000
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	21000
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	256000
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	107000
	us-gaap	Operating Lease Cost OperatingLeaseCost	695000
	us-gaap	Operating Lease Cost OperatingLeaseCost	247000
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	98000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	214000
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	65000
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	32000
	us-gaap	Variable Lease Cost VariableLeaseCost	238000
	us-gaap	Variable Lease Cost VariableLeaseCost	71000
CY2022Q3	us-gaap	Lease Cost LeaseCost	347000
CY2021Q3	us-gaap	Lease Cost LeaseCost	280000
	us-gaap	Lease Cost LeaseCost	1006000
	us-gaap	Lease Cost LeaseCost	663000
CY2022Q3	clnn	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-933000
CY2021Q3	clnn	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-533000
CY2022Q3	clnn	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-12000
CY2021Q3	clnn	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-21000
CY2022Q3	clnn	Finance Cash Flows From Finance Leases FinanceCashFlowsFromFinanceLeases	-101000
CY2021Q3	clnn	Finance Cash Flows From Finance Leases FinanceCashFlowsFromFinanceLeases	-117000
CY2022Q3	clnn	Total Term Loans TotalTermLoans	21466000
CY2021Q4	clnn	Total Term Loans TotalTermLoans	20736000
CY2022Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	977000
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1654000
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-4763000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-4598000
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	15726000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	14484000
	clnn	Schedule Of Future Payments Net Of Unamortized Debt Discounts ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts	<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Future principal payments under the 2021 Avenue Loan, net of unamortized debt discounts, if Avenue does not exercise the Conversion Feature, and under the 2022 MD Loan, net of unamortized debt discounts, are as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.997%;"/> <td style="width:1.623%;"/> <td style="width:1.0%;"/> <td style="width:12.878%;"/> <td style="width:1.0%;"/> <td style="width:1.623%;"/> <td style="width:1.0%;"/> <td style="width:12.878%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2021 Avenue Loan</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2022 MD Loan</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2022 (remainder)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,667</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13,333</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2025</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">369</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2026</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">313</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2027</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Thereafter</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Subtotal of future principal payments</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20,000</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">682</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Accrued and unpaid interest</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Less unamortized debt issuance costs and original issue discounts</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">948</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">19,052</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">666</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> </table>
CY2022Q3	clnn	Number Of Shares Issuable NumberOfSharesIssuable	4477045
CY2021Q4	clnn	Number Of Shares Issuable NumberOfSharesIssuable	4477045
CY2022Q3	us-gaap	Shares Issued SharesIssued	2407500
	clnn	Company Warrant Redemption Right CompanyWarrantRedemptionRight	We may redeem the outstanding warrants, in whole and not in part, at $0.01 per warrant if the last sales price of our Common Stock equals or exceeds $16.50 per share for any twenty trading days within a thirty-trading day period.
	clnn	Warrant Redemption Price Per Share WarrantRedemptionPricePerShare	0.01
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	16.50
CY2019Q3	clnn	Grants Received For Research GrantsReceivedForResearch	300000
CY2019Q3	clnn	Repayment Terms For Grant Received RepaymentTermsForGrantReceived	Pursuant to a Sponsored Research Agreement with NMSS, if we make future commercial sales of CNM-Au8 for the treatment of MS, we agreed to repay certain amounts based upon the following milestones: (i) 50% of the grant upon the first commercial product sale, (ii) an additional 50% of the grant upon cumulative sales of $10.0 million, (iii) an additional 150% of the grant upon cumulative sales of $50.0 million, and (iv) an additional 200% of the grant upon cumulative sales of $100.0 million, with the maximum repayment equal to 450% of the grant funding if all milestones are achieved. Additionally, if NMSS has not yet received repayments equal in the aggregate to 300% of the grant funding, then upon the closing of any of the following events we will repay 300% of the grant funding, or $1.0 million, less any amounts previously paid by us: (i) sale of all or substantially all of our assets and business, (ii) a public offering that occurs more than twelve months after completion of the biomarker research, (iii) sale of any portion of our assets and business including CNM-Au8 for the treatment of MS, (iv) exclusive licensing of our intellectual property claiming CNM-Au8 for the treatment of MS, and (v) a collaboration with a third-party to develop CNM-Au8 for the treatment of MS
CY2019Q3	us-gaap	Loss Contingency Managements Assessment And Process LossContingencyManagementsAssessmentAndProcess	Management’s estimate of the possible range of loss is between the minimum and maximum repayment amounts, equal to 50% and 450% of the grant funding, or approximately $0.2 million and $1.5 million, respectively. However, it is at least reasonably possible that Management’s estimate of the probability of occurrence of each contingent event and the possible range of loss will change in the near term.
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9432000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	29860000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-25787000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-11435000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1544000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-985000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3077000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2941000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10976000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	28875000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28864000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14376000
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	4500
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2098000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2425000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6484000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9945000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2098000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2425000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6484000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9945000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10395027
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.35
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M25D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	21082000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2865411
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.01
	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted	P9Y4M28D
	clnn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted	0
	clnn	Share Based Compensation Arrangement Number Of Options Exercised ShareBasedCompensationArrangementNumberOfOptionsExercised	1044448
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.27
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2641000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	42420
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.06
	clnn	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue	0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12173570
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.53
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10225000
CY2022Q3	clnn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber	6529233
CY2022Q3	clnn	Weighted Average Exercise Price Per Share Option Vested And Exercisable WeightedAverageExercisePricePerShareOptionVestedAndExercisable	2.33
	clnn	Weighted Average Exercise Price Weighted Average Remaining Term Years Options Vested And Eexercisable Ending WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding	P4Y9M21D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	10120000
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12173570
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.53
	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1	P6Y9M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	10225000
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	18100000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	18300000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M13D
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y18D
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62312097
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62312097
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10976000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	28944000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.24
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.85
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	29140000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-28864000
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	18000
CY2022Q3	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	11438000
CY2022Q3	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	1468000
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	736000
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	474000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	18100000
CY2021Q4	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	2317000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Milestone Three Shares Cancelled CleneNanomedicineContingentEarnoutMilestoneThreeSharesCancelled	2503851
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63541984
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63541984
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28864000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14163000
CY2022Q3	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0
CY2021Q3	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	196000
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10976000
	clnn	Unvested Restricted Stock Awards Shares UnvestedRestrictedStockAwardsShares	769139
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14163000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63508928
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62071754
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63234757
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61307699
CY2022Q3	clnn	Effect Of Potentially Dilutive Stock Options EffectOfPotentiallyDilutiveStockOptions	0
CY2021Q3	clnn	Effect Of Potentially Dilutive Stock Options EffectOfPotentiallyDilutiveStockOptions	5791023
	clnn	Effect Of Potentially Dilutive Stock Options EffectOfPotentiallyDilutiveStockOptions	0
	clnn	Effect Of Potentially Dilutive Stock Options EffectOfPotentiallyDilutiveStockOptions	0
CY2022Q3	clnn	Effective Of Potentially Dilutive Common Stock Warrants EffectiveOfPotentiallyDilutiveCommonStockWarrants	0
CY2021Q3	clnn	Effective Of Potentially Dilutive Common Stock Warrants EffectiveOfPotentiallyDilutiveCommonStockWarrants	1485049
	clnn	Effective Of Potentially Dilutive Common Stock Warrants EffectiveOfPotentiallyDilutiveCommonStockWarrants	0
	clnn	Effective Of Potentially Dilutive Common Stock Warrants EffectiveOfPotentiallyDilutiveCommonStockWarrants	0
CY2022Q3	clnn	Effect Of Potentially Dilutive Convertible Notes Payable EffectOfPotentiallyDilutiveConvertibleNotesPayable	0
CY2021Q3	clnn	Effect Of Potentially Dilutive Convertible Notes Payable EffectOfPotentiallyDilutiveConvertibleNotesPayable	482703
	clnn	Effect Of Potentially Dilutive Convertible Notes Payable EffectOfPotentiallyDilutiveConvertibleNotesPayable	0
	clnn	Effect Of Potentially Dilutive Convertible Notes Payable EffectOfPotentiallyDilutiveConvertibleNotesPayable	0
CY2022Q3	clnn	Effect Of Potentially Dilutive Unvested Restricted Stock Awards Shares EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares	0
CY2021Q3	clnn	Effect Of Potentially Dilutive Unvested Restricted Stock Awards Shares EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares	208105
	clnn	Effect Of Potentially Dilutive Unvested Restricted Stock Awards Shares EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares	0
	clnn	Effect Of Potentially Dilutive Unvested Restricted Stock Awards Shares EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares	0
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63508928
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70038634
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63234757
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61307699
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.42
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2022Q3	clnn	Convertible Notes Payables ConvertibleNotesPayables	482703
CY2021Q3	clnn	Convertible Notes Payables ConvertibleNotesPayables	0
	clnn	Convertible Notes Payables ConvertibleNotesPayables	482703
	clnn	Convertible Notes Payables ConvertibleNotesPayables	482703
CY2022Q3	clnn	Common Stock Warrants CommonStockWarrants	4477045
CY2021Q3	clnn	Common Stock Warrants CommonStockWarrants	2547934
	clnn	Common Stock Warrants CommonStockWarrants	4477045
	clnn	Common Stock Warrants CommonStockWarrants	4594545
CY2022Q3	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	12173570
CY2021Q3	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	2685575
	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	12173570
	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	9063423
CY2022Q3	clnn	Unvested Restricted Stock Awards Shares UnvestedRestrictedStockAwardsShares	769139
CY2021Q3	clnn	Unvested Restricted Stock Awards Shares UnvestedRestrictedStockAwardsShares	1100050
	clnn	Unvested Restricted Stock Awards Shares UnvestedRestrictedStockAwardsShares	1245489
CY2022Q3	clnn	Earnoutshares Earnoutshares	6592334
CY2021Q3	clnn	Earnoutshares Earnoutshares	9096185
	clnn	Earnoutshares Earnoutshares	6592334
	clnn	Earnoutshares Earnoutshares	9096185
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	24494791
CY2021Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15429744
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	24494791
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	24482345
CY2018Q3	clnn	Exclusive Rights Intellectual Property Term ExclusiveRightsIntellectualPropertyTerm	P5Y
CY2018Q3	clnn	Related Party Transaction Royalty Fee Rate For Revenues RelatedPartyTransactionRoyaltyFeeRateForRevenues	0.03
CY2022Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	171000
CY2021Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	98000
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	227000
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	500000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9753000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2022Q3	us-gaap	Revenues Revenues	174000
CY2021Q3	us-gaap	Revenues Revenues	110000
	us-gaap	Revenues Revenues	239000
	us-gaap	Revenues Revenues	524000
CY2022Q3	us-gaap	Depreciation Depreciation	233000
CY2021Q3	us-gaap	Depreciation Depreciation	235000
	us-gaap	Depreciation Depreciation	715000
	us-gaap	Depreciation Depreciation	734000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2098000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2425000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6484000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9945000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9805000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10450000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36736000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-35920000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9805000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10450000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36736000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-35920000
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1171000
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	39325000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7872000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21544000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10976000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	28875000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28864000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14376000
CY2022Q3	us-gaap	Assets Assets	36004000
CY2021Q4	us-gaap	Assets Assets	63063000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5296000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	661000

Files In Submission

Name	View Source	Status
0000950170-22-022333-index-headers.html	Edgar Link	pending
0000950170-22-022333-index.html	Edgar Link	pending
0000950170-22-022333.txt	Edgar Link	pending
0000950170-22-022333-xbrl.zip	Edgar Link	pending
clnn-20220930.htm	Edgar Link	pending
clnn-20220930.xsd	Edgar Link	pending
clnn-ex31_1.htm	Edgar Link	pending
clnn-ex31_2.htm	Edgar Link	pending
clnn-ex32_1.htm	Edgar Link	pending
clnn-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img180857224_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
clnn-20220930_def.xml	Edgar Link	unprocessable
clnn-20220930_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
clnn-20220930_pre.xml	Edgar Link	unprocessable
clnn-20220930_cal.xml	Edgar Link	unprocessable
clnn-20220930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLNN
Clene Inc. Stock $clnn

2022 Q4 Form 10-Q Financial Statement

#000095017022022333 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN Clene Inc. Stock $clnn

2022 Q4 Form 10-Q Financial Statement

#000095017022022333 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN
Clene Inc. Stock $clnn